APT Accelerator

Led by Professor Shampa Das, the APT Accelerator supports industry to develop new antibiotics and other antimicrobial agents to address unmet medical needs related to antimicrobial resistance.

The APT Accelerator has an extensive track record working with commercial companies and other entities such as F2G, Allecra, Pfizer, BioVersys, Antabio and FDA.

What we offer

We provide a complete, integrated drug development package covering:

  1. Experimental models for invasive bacterial and fungal diseases, including laboratory animal models, hollow fibre models of infection and other well characterised in vitro models of infection.
  2. Advanced PK-PD mathematical modelling, including population pharmacokinetics, drug interaction modelling, antimicrobial resistance modelling, and Monte Carlo simulation.
  3. Bioanalysis (LC/MS/MS run to GCP standards for laboratories).
  4. Preclinical imaging using MALDI-MSI to assess the distribution of small molecules in target tissues and organs.
  5. Training the next generation of researchers by hosting young investigators in our laboratories and running bespoke short courses, plus participation in expert workshops.
  6. A strong track record of publication in peer reviewed literature, knowledge of regulatory processes, and translation of findings from the laboratory to the clinic.
  7. Deep clinical knowledge of Infectious Diseases and Clinical Microbiology.

Expertise and infrastructure

Experimental pharmacology and pharmacodynamics

APT has extensive infrastructure, expertise and track record in experimental pharmacodynamics. We have many well characterised in vitro and in vivo models of infection, including hollow fibre infection models (HFIM) that are now widely accepted by regulatory authorities. HFIM are especially valuable for an understanding of the development of AMR and are increasingly used in drug development.

Advanced pharmacokinetic modelling and simulation

APT has advanced state-of-the-art techniques in quantitative pharmacology that includes PK-PD modelling, population pharmacokinetics, Monte Carlo simulation, optimal design theory, and modelling of the emergence of AMR.

Preclinical imaging

APT has made a major investment in MALDI-MSI to assess the spatial distribution of small molecules in target tissues and organs.

Bioanalytical sciences

APT has state-of-the art LC/MS/MS machines that enable the quantification of drug concentrations within clinically relevant matrices.

Back to: Institute of Systems, Molecular and Integrative Biology